Compounds > ochraceolide a
Page last updated: 2024-11-08

ochraceolide a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ochraceolide A: structure given in first source; isolated from Kokoona ochracea stem bark [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Kokoonagenus[no description available]CelastraceaeA plant family of the order Celastrales, subclass Rosidae, class Magnoliopsida.[MeSH]
Kokoona ochraceaspecies[no description available]CelastraceaeA plant family of the order Celastrales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID386922
CHEMBL ID512065
MeSH IDM0199005

Synonyms (9)

Synonym
nsc-680072
NCI60_028560
nsc680072
ochraceolide a
CHEMBL512065
hexamethyl(methylene)[?]dione
(1r,2r,5r,10r,11r,14r,15s,16r,20r,22s)-1,2,6,6,10,22-hexamethyl-17-methylidene-19-oxahexacyclo[12.10.0.02,11.05,10.015,22.016,20]tetracosane-7,18-dione
AKOS040753346
6ar,6 br,8as,9ar,12ar,14br)-4,4,6a,6 b,8a,14b-hexamethyl-12-methyleneicosahydro-3h-phenanthro[1',2':6,7]indeno[2,1-b]furan-3,11(2h)-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1228705Selectivity index, ratio of CC50 for mock-infected human MT2 cells to IC50 for HIV1 NL4.3-Ren infected in human MT2 cells2015Journal of natural products, May-22, Volume: 78, Issue:5
Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina.
AID354974Inhibition of recombinant protein farnesyltransferase-mediated [3H]FPP transfer after 30 mins by scintillation counting1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID334865Cytotoxicity against human KB cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID1228703Cytotoxicity against mock-infected human MT2 cells assessed as reduction in cell viability incubated for 48 hrs by cell-titer Glo assay2015Journal of natural products, May-22, Volume: 78, Issue:5
Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina.
AID338753Cytotoxicity against human UISO-COL2 cells after 72 hrs
AID334859Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID338758Cytotoxicity against human UISO-LUC1 cells after 72 hrs
AID334861Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID338754Cytotoxicity against human KB3 cells after 72 hrs
AID334858Cytotoxicity against mouse P388 cells2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID334863Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID334862Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID334860Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID338757Cytotoxicity against human UISO-MEL2 cells after 72 hrs
AID354977Cytotoxicity against human Lu1 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID354981Cytotoxicity against human A431 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID334903Growth inhibition of human KB cells implanted intraperitoneally to NCr nu/nu mouse at 553.1 umol/kg, ip administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID338756Cytotoxicity against human HT1080 cells after 72 hrs
AID354979Cytotoxicity against human KB cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID1228702Antiviral activity against HIV1 NL4.3-Ren infected in human MT2 cells assessed as inhibition of viral growth at 10 uM measured 48 hrs post infection by luminometry2015Journal of natural products, May-22, Volume: 78, Issue:5
Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina.
AID334904Growth inhibition of human KB cells implanted subcutaneously to NCr nu/nu mouse at 553.1 umol/kg, ip administered from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID354980Cytotoxicity against human KBVIN cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID338755Cytotoxicity against human KBV1 cells after 72 hrs
AID354978Cytotoxicity against human SK-MEL-2 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID354982Cytotoxicity against human LNCAP cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID354975Cytotoxicity against human BC1 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID335167Toxicity in NCr nu/nu mouse subcutaneously implanted with human KB cells assessed as body weight change at 553.1 umol/kg, ip administered from day 3 to 6 after implantation measured on day 72002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID334867Cytotoxicity against human BC1 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID338752Cytotoxicity against human UISO-BCA1 cells after 72 hrs
AID354983Cytotoxicity against human ZR-75-1 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID354984Cytotoxicity against human U373 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID338751Cytotoxicity against mouse P388 cells after 48 hrs
AID1228704Antiviral activity against HIV1 NL4.3-Ren infected in human MT2 cells assessed as inhibition of viral growth measured 48 hrs post infection by luminometry2015Journal of natural products, May-22, Volume: 78, Issue:5
Isolation, Structural Modification, and HIV Inhibition of Pentacyclic Lupane-Type Triterpenoids from Cassine xylocarpa and Maytenus cuzcoina.
AID334857Inhibition of protein farnesyltransferase2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID334868Cytotoxicity against human SW626 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID354985Cytotoxicity against human Col2 cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID334864Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
AID354976Cytotoxicity against human HT cells1996Journal of natural products, Jul, Volume: 59, Issue:7
Lupane derivatives from Lophopetalum wallichii with farnesyl protein transferase inhibitory activity.
AID334866Cytotoxicity against human Col2 cells after 72 hrs by SRB assay2002Journal of natural products, Jun, Volume: 65, Issue:6
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's1 (25.00)24.3611
2020's1 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiazoles
[no description available]		2.41101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		2.4320diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
alpha-lapachone
alpha-lapachone: structure in first source		2.0110organic heterotricyclic compound;
organooxygen compound
lupenone
lupenone: structure in first source		2.1110triterpenoidmetabolite
diosgenin
[no description available]		2.01103beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal		antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite
dioscin
[no description available]		2.0110hexacyclic triterpenoid;
spiroketal;
spirostanyl glycoside;
trisaccharide derivative		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 1.14.18.1 (tyrosinase) inhibitor;
hepatoprotective agent;
metabolite
lupeol
[no description available]		2.4320pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
bevirimat
bevirimat: an HIV inhibitor; disrupts late step in processing HIV Major Core Protein p24, preventing the capsid precursor p25 from being converted to mature capsid p24. bevirimat : A pentacyclic triterpenoid obtained by the formal condensation of 2,2-dimethylsuccinic acid with the 3-hydroxy group of betulinic acid. It is isolated from the Chinese herb Syzygium claviflorum. The first in the class of HIV-1 maturation inhibitors to be studied in humans, bevirimat was identified as a potent HIV drug candidate and several clinical trials were conducted, but development into a new drug was plagued by numerous resistance-related problems.		2.1110dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid		HIV-1 maturation inhibitor;
metabolite
betulonal
betulonal: originally isolated from white birch bark (Betula pendula); structure in first source		2.1110
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.0110
betulin-3-caffeate
betulin-3-caffeate: has antineoplastic activity; isolated from Hibiscus syriacus; structure in first source		2.1110
betulone
[no description available]		2.1110triterpenoidmetabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.0110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0110
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.0110
Malignant Melanoma
[description not available]		02.0110
Cancer of Ovary
[description not available]		02.0110
Cancer of Prostate
[description not available]		02.0110
Colonic Neoplasms
Tumors or cancer of the COLON.		02.0110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.0110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.0110
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0110